Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
Clinical trial NCT03778229 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03778229
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-09
- Primary completion
- 2024-08-23
- Enrollment
- 367
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.